|
|
The CEPIfunded study will evaluate the safety, tolerability, and immunogenicity of IAVIs single dose Lassa fever vaccine candidateKey takeaways:Participants in Nigeria have been vaccinated with a Lassa fever vaccine candidate in the first Phase 2 clinical trial of any Lassa vaccine.Lassa fever is a deadly hemorrhagic fever common to West Africa. No approved vaccine currently exists.... Lire le communiqué |
|
| |
|
| |
|
|
TB kills 1.3 million people a year and sickens more than 10 million people annually.A new TB vaccine is needed to reach the global End TB goals.MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.Grant from the Bill & Melinda Gates Fou... Lire le communiqué |
|
| |
|
| |
|
|
NEW YORK, NY / ACCESSWIRE / July 7, 2023 / IAVI is pleased to announce that a new award has been granted by the German government to help support the latestage development of a promising tuberculosis TB vaccine candidate, MTBVAC.The German Federal Ministry of Education and Research BMBF through the KfW Development Bank has committed to contribute €9.2 million to IAVI ove... Lire le communiqué |
|
| |
|
| |
|
|
NEW YORK, NY / ACCESSWIRE / June 27, 2023 / IAVI announced today that the first participants have been vaccinated with a Sudan virus SUDV vaccine candidate in a firstinhuman Phase I clinical trial in the U.S. The IAVIsponsored trial is funded by the Biomedical Advanced Research and Development Authority BARDA, part of the Administration for Strategic Preparedness and Response ASPR within the U.S.... Lire le communiqué |
|
| |
|
| |
|
|
TB kills 1.6 million people a year, causing more deaths than any other single infectious disease apart from COVID19, and sickens more than 10 million people annually.A new TB vaccine is needed to reach global END TB goals.MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents... Lire le communiqué |
|
| |
|
| |
|
|
NEW YORK, NY / ACCESSWIRE / March 2, 2023 / IAVI announced today the Biomedical Advanced Research and Development Authority BARDA, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, funded additional development and testing of IAVIs singledose vaccine candidates against the filoviruses Marburg virus MARV and Sudan ebolavirus... Lire le communiqué |
|
| |
|
| |
|
|
Merck will provide the investigational vaccine based on a proven platform technologyNEW YORK, NY / ACCESSWIRE / October 25, 2022 / IAVI, a nonprofit scientific research organization, and Merck, known as MSD outside the United States and Canada, have entered into an agreement that could enable IAVI to accelerate the entry of a promising Sudan ebolavirus SUDV vaccine candidate that IAVI is developi... Lire le communiqué |
|
| |
|
| |
